A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Cancer Clinical Trial

Official title:

Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05001282
• Other study ID #: ELU-FRa-1
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: September 13, 2021
• Est. completion date: June 15, 2025

Study information

• Verified date: March 2024
• Source: Elucida Oncology
• Contact: Clinical Trial Operations
• Phone: 732-823-1182
• Email: clinicaltrialinfo[@]elucidaoncology.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study, ELU- FRα-1, is focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available.

ELU001 is a new chemical entity described as a C'Dot drug conjugate (CDC), consisting of payloads (exatecans) and targeting moieties (folic acid analogs) covalently bound by linkers to the C'Dot particle carrier. ELU001 will be the first drug-conjugate of its kind to be introduced into the clinic, a first in class, and a novel molecular entity.

Description:

The study has two parts: Part 1 Dose Escalation Safety Study to identify the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D), and Part 2 Tumor Group Expansion Cohort(s) where specific cancer types will be evaluated for efficacy and safety at the RP2D.

Part 1, subjects with cancer types with a high likelihood of having FRα overexpressing tumors based on historical data, specifically, ovarian, endometrial, colorectal, gastric, gastroesophageal junction, triple negative breast, or non-small cell lung cancers, or cholangiocarcinoma, will be enrolled in a basket clinical study. Retrospective analysis of folate receptor alpha (FRα) expression status will be determined. Part 1 is currently closed for further recruitment.

Part 2 Stage 1 of a Simon's Two-Stage design, tumor group expansion cohorts, each consisting of subjects with cancer types studied as part of the basket in Part 1. Part 2 is open for recruitment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 166
• Est. completion date: June 15, 2025
• Est. primary completion date: June 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

Patients must meet the following criteria to enroll in this study:

• Part 1 Documented diagnosis of ovarian cancer, endometrial cancer, colorectal cancer, gastric cancer, gastroesophageal junction cancer, triple negative breast cancer, non-small cell lung cancer, or cholangiocarcinoma

• Part 2 Ovarian Cancer or Endometrial Cancer

• No other meaningful life-prolonging therapy option available

• Must provide archival tumor tissue or a newly obtained tumor biopsy specimen prior to the first dose of ELU001 for folate receptor alpha (FRa) expression analysis. Previous FRa expression test results may be used in certain circumstances

• Adequate organ function

• Measurable disease, or in the absence of measurable disease, non-measurable disease as per Response evaluation criteria in solid tumors (RECIST) v1.1

• Part 1: Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2; Part 2: ECOG performance status of 0 or 1.

• Recovered from previous surgeries

• Agree to highly effective contraception, not to get pregnant, or for men, not father a child during study participation

Key Exclusion Criteria:

Patients who meet any of the following are not eligible to enroll in this study:

• Clinically significant eye disorders

• Taken any treatments that use the protein folate receptor alpha or FRa to work

• Taken any other experimental treatments

• History of significant cardiac issues or other cancers within 3 years.

• Significant anemia, significant neutropenia, or significant thrombocytopenia (e.g., not enough platelets in your blood - platelets held stop bleeding in your body)

• Detectable viral load for HIV (human immunodeficiency virus), hepatitis B or C.

• If you are pregnant.

• Part 1: Cannot have active autoimmune diseases such as rheumatoid arthritis, SLE (systemic lupus erythematosus), ulcerative colitis, Crohn's Disease, MS (multiple sclerosis), ankylosing spondylitis, thyroiditis that require treatments that suppress your immune system.

• Part 1: if your cancer has spread to your brain.

• Part 2: You can have cancer that has spread to your brain but there are exceptions. The cancer in your brain cannot be causing any symptoms, it cannot be larger than 3 cm, there can be no evidence on a scan that shows your brain tissue has shifted from its expected position inside the skull (called "herniation") or be bleeding in the skull or brain itself (called "hemorrhage").

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma, Endometrioid
• Carcinoma, Ovarian Epithelial
• Carcinosarcoma
• Endometrial Adenocarcinoma
• Endometrial Cancer
• Endometrial Cancer Recurrent
• Endometrial Carcinosarcoma
• Endometrial Clear Cell Adenocarcinoma
• Endometrial Diseases
• Endometrial Neoplasms
• Endometrioid Adenocarcinoma
• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Neoplasms
• Ovarian Adenocarcinoma
• Ovarian Cancer
• Ovarian Cancer Recurrent
• Ovarian Cancer Stage
• Ovarian Carcinoma
• Ovarian Diseases
• Ovarian Epithelial Cancer
• Ovarian Neoplasm Epithelial
• Ovarian Neoplasms
• Ovarian Serous Adenocarcinoma
• Ovary Cancer
• Ovary Disease
• Ovary Neoplasm
• Peritoneal Cancer
• Recurrence
• Uterine Diseases

Intervention

Drug:
• ELU001
Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)

Locations

Country	Name	City	State
United States	Cleveland Clinic	Cleveland	Ohio
United States	Mary Crowley Cancer Research	Dallas	Texas
United States	Duke University Medical Center - Duke Cancer Institute	Durham	North Carolina
United States	Providence Medical Foundation	Fullerton	California
United States	Hope and Healing Cancer Services	Hinsdale	Illinois
United States	Mayo Clinic - Jacksonville, FL	Jacksonville	Florida
United States	D&H Cancer Research Center	Margate	Florida
United States	Sarah Cannon Research Institute at Tennessee Oncology	Nashville	Tennessee
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Sarah Cannon Research Institute at Florida Cancer Specialists	Orlando	Florida
United States	OSF Saint Francis Medical Center	Peoria	Illinois
United States	Thomas Jefferson University, Sidney Kimmel Cancer Center	Philadelphia	Pennsylvania
United States	Mayo Clinic - Phoenix, AZ	Phoenix	Arizona
United States	Women & Infants Hospital of Rhode Island	Providence	Rhode Island
United States	Mayo Clinic - Rochester, MN	Rochester	Minnesota
United States	New Experimental Therapeutics of San Antonio (NEXT Oncology)	San Antonio	Texas
United States	Fred Hutchinson Cancer Center	Seattle	Washington
United States	Avera Cancer Institute	Sioux Falls	South Dakota

Sponsors (1)

Lead Sponsor	Collaborator
Elucida Oncology

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1 Dose Escalation: The Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ELU001 for IV infusion in patients with over-expressing Folate Receptor Alpha tumors.	To determine the MTD and/or RP2D of ELU001 in patients with over-expressing Folate Receptor Alpha tumors. When at least 2 out of 6 patients in a given dose-level experience a dose-limiting toxicity (DLT), the dose is considered to have exceeded the MTD. The MTD, therefore, is defined as the previous highest tested dose of ELU001 that did not cause a DLT in the first cycle of treatment. In the event of emerging data during Part 1, the Sponsor may, in consultation with a dose-level safety review group, decide to define a recommended dose for expansion (in for Part 2) (RP2D) instead of the MTD. DLTs are defined as a treatment-emergent adverse event (TEAE) or abnormal laboratory value related to ELU001 treatment that result in a failure to meet the criteria for re-treatment.	28 days
Primary	Part 2 Dose Expansion: To determine overall response rate (ORR) (complete response [CR] + partial response [PR]) of ELU001 for IV infusion in patients with over-expressing Folate Receptor Alpha tumors, per RECIST v1.1.	Percentage of Participants with confirmed objective response as assessed by the investigator and per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 CR is defined as the disappearance of all target or non-target lesions. PR is defined as at least 30 percent (%) decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.	First dose of study drug until responses of CR or PR, assessed up to 12 months.
Secondary	Part 1 Dose Escalation: To determine overall response rate (ORR) (complete response [CR] + partial response [PR]) of ELU001 for IV infusion in patients with over-expressing Folate Receptor Alpha tumors, per RECIST v1.1.	Percentage of Participants with confirmed objective response as assessed by the investigator and per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 CR is defined as the disappearance of all target or non-target lesions. PR is defined as at least 30 percent (%) decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.	First dose of study drug until responses of CR or PR, assessed up to 12 months.
Secondary	Part 1 and Part 2: To determine Duration of Response (DOR) of ELU001 for IV infusion in patients with over-expressing Folate Receptor Alpha tumors.	Time Measurement: DOR will begin at the date that a response has been identified (stable disease, partial response, or complete response) until the date of progressive disease (PD). PD is defined of at least a 20% increase in the sum of the longest diameters of the target lesions from data of initial response.	Date of first response (CR or PR) until the date of disease progression or up to 12 months, whichever occurs first.
Secondary	Part 1 and Part 2: Number of participants with adverse events as assessed by CTCAE v5.0 Safety Evaluations.	The number of participants Frequency/severity of abnormalities in vital signs measurements, physical examination findings, changes in clinical laboratory parameters, and incidence of adverse events after taking ELU001.	First dose of study drug up to 28 days after the last dose of study drug or up to 12 months, whichever occurs first.

External Links

•   Elucida Oncology Corporate Website